Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer

Nature

Volumn 493, Issue 7432, 2013, Pages 406-410

  Ruark, Elise ^a   Snape, Katie ^a   Humburg, Peter ^b   Loveday, Chey ^a   Bajrami, Ilirjana ^a   Brough, Rachel ^a   Rodrigues, Daniel Nava ^a   Renwick, Anthony ^a   Seal, Sheila ^a   Ramsay, Emma ^a   Duarte, Silvana Del Vecchio ^a   Rivas, Manuel A ^b,c   Warren Perry, Margaret ^a   Zachariou, Anna ^a   Campion Flora, Adriana ^a   Hanks, Sandra ^a   Murray, Anne ^a   Pour, Naser Ansari ^a   Douglas, Jenny ^a   Gregory, Lorna ^b   Rimmer, Andrew ^b   Walker, Neil M ^d   Yang, Tsun Po ^e   Adlard, Julian W ^f   Barwell, Julian ^g   Berg, Jonathan ^h   Brady, Angela F ⁱ   Brewer, Carole ^j   Brice, Glen ^k   Chapman, Cyril ^l   Cook, Jackie ^m   Davidson, Rosemarie ⁿ   Donaldson, Alan ^o   Douglas, Fiona ^p   Eccles, Diana ^q   Gareth Evans, D ^r   Greenhalgh, Lynn ^s   Henderson, Alex ^p   Izatt, Louise ^t   Kumar, Ajith ^u   Lalloo, Fiona ^r   Miedzybrodzka, Zosia ^v   Morrison, Patrick J ^w   Paterson, Joan ^x   Porteous, Mary ^y   Rogers, Mark T ^z   Shanley, Susan ^aa   Walker, Lisa ^ab   Gore, Martin ^aa   Houlston, Richard ^a   Brown, Matthew A ^ac   Caufield, Mark J ^ad   Deloukas, Panagiotis ^e   McCarthy, Mark I ^b,ae,af   Todd, John A ^d   Turnbull, Clare ^a,aa   Reis Filho, Jorge S ^a   Ashworth, Alan ^a   Antoniou, Antonis C ^d   Lord, Christopher J ^a   Donnelly, Peter ^b,ag   Rahman, Nazneen ^a,aa   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^h UNIVERSITY OF DUNDEE   (United Kingdom)

ⁱ Kennedy Galton Centre   (United Kingdom)

^j ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^k ST GEORGE S HOSPITAL   (United Kingdom)

^l BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^m SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

ⁿ SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^o UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^p NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^q UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^r ST MARY S HOSPITAL   (United Kingdom)

^s LIVERPOOL WOMEN'S NHS FOUNDATION TRUST   (United Kingdom)

^t GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^u GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^v UNIVERSITY OF ABERDEEN   (United Kingdom)

^w QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^x CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^y WESTERN GENERAL HOSPITAL   (United Kingdom)

^z UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^aa INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^ab OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^ac UNIVERSITY OF QUEENSLAND   (Australia)

^ad QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^ae UNIVERSITY OF OXFORD   (United Kingdom)

^af CHURCHILL HOSPITAL   (United Kingdom)

^ag UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CATALYSIS; ENZYME ACTIVITY; GENETIC VARIATION; HEALTH RISK; IRRADIATION; MUTATION; PROTEIN; WOMENS HEALTH;

ALLELE; ARTICLE; BASE PAIRING; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CATALYSIS; CONTROLLED STUDY; DNA REPAIR; EXON; FEMALE; GAIN OF FUNCTION MUTATION; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IONIZING RADIATION; LOSS OF FUNCTION MUTATION; LYMPHOCYTE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN P53 INDUCIBLE PROTEIN PHOSPHATASE GENE;

ALLELES; BREAST NEOPLASMS; CLUSTER ANALYSIS; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISOENZYMES; LYMPHOCYTES; MOSAICISM; MUTATION; OVARIAN NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

PERU TOMATO MOSAIC VIRUS;

EID: 84872621246     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11725     Document Type: Article

References (40)

1. Cirulli, E. T.&Goldstein,D.B.Uncovering theroles of rare variants incommondisease through whole-genome sequencing. Nature Rev. Genet. 11, 415-425 (2010).
2. Turnbull, C. & Rahman, N. Genetic predisposition to breast cancer: past, present, and future. Annu. Rev. Genomics Hum. Genet. 9, 321-345 (2008).
3. Gayther, S. A. & Pharoah, P. D. The inherited genetics of ovarian and endometrial cancer. Curr. Opin. Genet. Dev. 20, 231-238 (2010).
4. Rahman, N. et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genet. 39, 165-167 (2007).
5. Renwick, A. et al. ATMmutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature Genet. 38, 873-875 (2006).
6. Seal, S. et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are lowpenetrance breast cancer susceptibility alleles. Nature Genet.38, 1239-1241(2006).
7. Meijers-Heijboer, H. et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2mutations. Nature Genet. 31, 55-59 (2002).
8. Meindl,A. et al.Germlinemutations inbreastandovariancancerpedigrees establish RAD51C as a human cancer susceptibility gene. NatureGenet. 42, 410-414 (2010).
9. Loveday, C. et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nature Genet. 44, 475-476 (2012).
10. Loveday, C. et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genet. 43, 879-882 (2011).
11. Rivas,M.A. et al.DeepresequencingofGWASloci identifies independentrare variants associated with inflammatory bowel disease. Nature Genet. 43, 1066-1073 (2011).
12. Snape, K. et al. Predisposition gene identification in common cancers by exome sequencing: insights from familial breast cancer. Breast Cancer Res. Treat. 134, 429-433 (2012).
13. Caruccio, N. Preparation of next-generation sequencing libraries using Nextera technology: simultaneous DNA fragmentation and adaptor tagging by in vitro transposition. Methods Mol. Biol. 733, 241-255 (2011).
14. Schouten, J.P. et al. Relative quantification of40 nucleic acidsequences bymultiplex ligation-dependent probe amplification. Nucleic Acids Res. 30, e57 (2002).
15. Fiscella, M. et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Natl Acad. Sci. USA 94, 6048-6053 (1997).
16. Lu, X. et al. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27, 123-135 (2008).
17. Lu, X.,Nguyen, T. A.&Donehower, L. A. Reversal of the ATM/ATR-mediatedDNA damage response by the oncogenic phosphatase PPM1D. Cell Cycle 4, 4060-4064 (2005).
18. Shreeram, S. et al. Regulation of ATM/p53-dependent suppression of mycinduced lymphomas by Wip1 phosphatase. J. Exp. Med. 203, 2793-2799 (2006).
19. Fujimoto, H. et al. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ. 13, 1170-1180 (2006).
20. Bulavin, D. V. et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nature Genet. 31, 210-215 (2002).
21. Natrajan, R. et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin. Cancer Res. 15, 2711-2722 (2009).
22. Tan, D. S. et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin. Cancer Res. 15, 2269-2280 (2009).
23. Rayter, S. et al. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene 27, 1036-1044 (2008).
24. Hayashi, R. et al. Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1). Biochemistry 50, 4537-4549 (2011).
25. Chuman, Y. et al. PPM1D430, a novel alternative splicing variant of the human PPM1D, can dephosphorylate p53 and exhibits specific tissue expression. J. Biochem. 145, 1-12 (2009).
26. Silva, A. L., Ribeiro, P., Inacio, A., Liebhaber, S. A. & Romao, L. Proximity of the poly(A)-binding protein to a premature termination codon inhibits mammalian nonsense-mediated mRNA decay. RNA 14, 563-576 (2008).
27. Jacobs, K. B. et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nature Genet. 44, 651-658 (2012).
28. Laurie, C. C. et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nature Genet. 44, 642-650 (2012).
29. Barnes, D. R. et al. Evaluation of assosciation methods for analysing modifiers of diseaseriskincarriers ofhighriskmutations.Genet. Epidemiol.36,274-291(2012).
30. Antoniou, A. C. & Easton, D. F. Polygenic inheritance of breast cancer: implications for design of association studies. Genet. Epidemiol. 25, 190-202 (2003).
31. Tavassoli, F. A. & Devilee, P. in Pathology and Genetics of Tumours of the Breast and Female Genital Organs (IARC, 2003).
32. Hernandez, L. et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J. Pathol. 227, 42-52 (2012).
33. Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nature Biotechnol. 27, 182-189 (2009).
34. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
35. Turnbull, C. et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nature Genet. 42, 504-507 (2010).
36. Lunter, G. & Goodson, M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res. 21, 936-939 (2011).
37. Rimmer, A., Mathieson, I., Lunter, G. & McVean, G. Platypus: An Integrated Variant Caller (http://www.well.ox.ac.uk/platypus) (2012).
38. Curado, M. P. et al. Cancer incidence in five continents, Volume VIII. IARC Sci. Publ. No 160, 1-781 (2002).
39. Antoniou, A. C. et al. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet. Epidemiol. 21, 1-18 (2001).
40. Lange, K., Weeks, D. & Boehnke, M. Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE. Genet. Epidemiol. 5, 471-472 (1988).